These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19900256)

  • 21. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM; Figlin RA; Hutson TE; Michaelson MD; Kim ST; Baum CM; Kattan MW
    Cancer; 2008 Oct; 113(7):1552-8. PubMed ID: 18720362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 24. A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.
    Rosenblad AK; Sundqvist P; Westman B; Ljungberg B
    Qual Life Res; 2021 Sep; 30(9):2663-2670. PubMed ID: 33846957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term response with sunitinib for metastatic renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
    Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

  • 29. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
    Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
    Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
    Bergerot CD; Malhotra J; Bergerot P; Philip EJ; Castro DV; Hsu J; Mota ACA; Cardoso de Azeredo A; Neto JNM; Hutson T; Grünwald V; Bex A; Psutka SP; Rini B; Plimack ER; Master V; Albiges L; Choueiri TK; Pal S; Powles T
    Oncologist; 2023 Jun; 28(6):494-500. PubMed ID: 36917626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.
    Bacik J; Mazumdar M; Murphy BA; Fairclough DL; Eremenco S; Mariani T; Motzer RJ; Cella D
    Qual Life Res; 2004 Feb; 13(1):137-54. PubMed ID: 15058795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploration of baseline patient-reported side effect bother from cancer therapy.
    Roydhouse JK; King-Kallimanis BL; Roy P; Weinstock C; Krol D; Daniels SR; Suzman DL; Beaver JA; Kluetz PG
    Clin Trials; 2020 Jun; 17(3):332-337. PubMed ID: 32153216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Butt Z; Peipert J; Webster K; Chen C; Cella D
    Cancer; 2013 Jan; 119(2):429-37. PubMed ID: 22778010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a scale to measure the quality of patient medication counseling using Rasch model.
    Tran VD; Dorofeeva VV; Loskutova EE
    Pharm Pract (Granada); 2018; 16(4):1327. PubMed ID: 30637035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.